SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to recent service outages affecting its 365 suite and ongoing debate surrounding its AI strategy and investment in OpenAI, amplified by Elon Musk's lawsuit. While some investors see current price levels as an opportune moment to buy a fundamentally strong company, others point to broader mega-cap tech weakness and competitive pressures as key drivers of the decline ahead of its earnings report.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed (PAVM) is trending due to news that its subsidiary, Lucid Diagnostics, secured a contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access across the VA healthcare system. This has ignited intense market activity and debate, with some investors anticipating significant further upside given the contract's potential and the company's low share float, while others express caution regarding extreme price volatility and the potential for future share offerings.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility amid intense community debate, driven by reports of potential lawsuits from bondholders concerning the financing of its large-scale AI infrastructure projects and substantial debt. While some investors view the recent price action as a major buying opportunity given Oracle's strategic position in cloud and AI, others are wary of the financial liabilities and the long-term impact on the company. The ongoing speculation regarding a significant TikTok deal is also a key point of discussion, contributing to divergent market sentiment.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is experiencing a notable sell-off, generating intense community discussion over its future. While many express strong bearish sentiment citing competition in the GLP-1 market and perceived threats from Amazon, others view the downturn as an oversold buying opportunity, emphasizing the company's expanding personalized healthcare platform and vertical integration.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is a focal point for intense market volatility, driven by shifting geopolitical narratives concerning presidential statements on Greenland and evolving US-EU trade relations. Community sentiment is sharply divided, with some anticipating continuous "V-shape" rallies and "buy the dip" opportunities fueled by perceived pro-market stances, while others remain highly skeptical, warning of orchestrated pump-and-dump scenarios and a looming market decline. This tug-of-war reflects deep uncertainty within the tech-heavy Nasdaq, where bullish convictions clash with cautious perspectives on broader economic stability.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai (BBAI) is trending due to an upcoming pivotal shareholder vote on increasing authorized shares, which has polarized the community. While some investors fear potential dilution, many anticipate the approval will unlock significant growth, enabling future contracts and strategic moves in the government AI and defense sectors that could drive a substantial re-rating.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending following news of a significant French government-backed deal to establish a rare earth metals and alloys production facility in Europe, aiming to bolster the integrated supply chain for the U.S. and its allies. This development, alongside broader sector momentum driven by geopolitical dynamics and the launch of new leveraged ETFs, is fueling community discussions about the company's long-term potential and notable price volatility. Traders are actively discussing the broader implications of securing critical minerals supply chains and the company's "mine-to-magnet" strategy amidst ongoing market swings.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is trending following its selection for the U.S. Missile Defense Agency's SHIELD contract, a significant validation of its capabilities in defense AI that positions it for substantial 'Golden Dome' task orders. The community is actively discussing the company's expanding footprint into sovereign AI initiatives, particularly in the Middle East, with many viewing recent price dips as strategic buying opportunities. This perceived shift toward high-value government and international AI contracts is fueling anticipation for a significant re-rating of INOD's valuation.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending after reporting strong Q4 results driven by subscriber and ad revenue growth, though its stock faces downward pressure from softer Q1 guidance and ongoing speculation around a potential Warner Bros. Discovery acquisition. The community is sharply divided, with many viewing the dip as a prime buying opportunity for a market leader, while others anticipate further declines given the acquisition's perceived risks and potential for market manipulation.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony is trending following its recent acquisition of a critical minerals flotation facility, strengthening its integrated processing capabilities amidst a heightened national security focus. The community is actively discussing the company's unique position as a domestic antimony producer, anticipating significant government investment in critical mineral supply chains and potential for substantial upside. Many are closely watching for further strategic announcements as geopolitical tensions underscore the importance of securing domestic resource supply.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Enveric stated that with the molecules covered by the patent, it may be able to target key receptors in new ways.</li><li>The company said this could enable the development of drug candidates with efficacy and safety profiles previously unattainable.</li><li>Enveric added that the expanded pipeline of molecules protected by patents allows it to license and partner with pharmaceutical firms that are investing in the treatment of neuropsychiatric conditions.</li></ul>Enveric Biosciences Inc. (SOPA) shares gained over 7% in Monday’s pre-market trade after the company announced that it has been issued a patent that covers novel molecules with likely applications for the treatment of neuropsychiatric conditions.The company said that U.S. Patent No. 12,492,179 extends the protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences</a> trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Licensing Opportunity</h2>Enveric stated that with the molecules covered by the patent, it may be able to target key receptors in new ways. The company said this could enable the development of drug candidates with efficacy and safety profiles previously unattainable.Enveric added that the expanded pipeline of molecules protected by patents allows it to license and partner with pharmaceutical firms that are investing in the treatment of neuropsychiatric conditions.<h2 class="st-heading-2">Patent Details</h2>Enveric stated that the molecules covered by this patent are based on known compounds with relevant pharmacological activity. It added that these compounds are chemically altered to improve efficacy while reducing side effects compared to existing compounds.“Enveric’s growing pipeline of patented molecules expands the available opportunities to develop next-generation treatments for neuropsychiatric conditions, leveraging our innovative research,” said Enveric CEO Joseph Tucker.Enveric is a Massachusetts-based biotechnology company focused on developing small-molecule neuroplastogenic therapeutics for the treatment of psychiatric and neurological disorders.<a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> is down 99.6% year-to-date and 99.5% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paul-krugman-warns-2026-worse-for-small-businesses/cL75twFRExT">Paul Krugman Warns 2026 Will Be Worse For Small Businesses, A Month After Small Firms Cut 120,000 Jobs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is ENVB Stock Rising Today?

The company said that U.S. Patent No. 12,492,179 extends the protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules.

Equity

Enveric Biosciences Announces Patent Issuance

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders...

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological...

<ul class="summary-bullets"><li>The USPTO’s Notice of Allowance signals that the agency has determined the patent is likely to be granted.</li><li>By securing this intellectual property, Enveric gains a competitive edge in the neuropsychiatric treatment space.</li><li>Enveric’s stock surged 106% in Wednesday’s premarket.</li></ul>Enveric Biosciences (ENVB) stock is drawing investors' attention on Wednesday after the company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application covering its EVM301 Series of molecules.<a href="https://stocktwits.com/symbol/ENVB/sentiment">Enveric’s stock</a> traded over 106% higher in Wednesday’s premarket.&nbsp;<h2 class="st-heading-2">Patent Focus and Potential</h2>The USPTO’s Notice of Allowance signals that the agency has determined the patent is likely to be granted, providing Enveric with intellectual property protection for its neuroplastogenic compounds.“We believe EB-003 holds great potential as the first known compound designed to selectively engage both 5-HT₂A and 5-HT₁B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects, while being specifically designed to promote neuroplasticity and minimize hallucinogenic effects, allowing administration in outpatient setting,” said Joseph Tucker, CEO, Enveric.&nbsp;By securing this intellectual property, Enveric gains a competitive edge in the neuropsychiatric treatment space, particularly for patients with limited therapeutic options. The patent also enhances the company’s ability to pursue future research and commercialization of its EVM301 compounds.<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2>The stock was the second-most trending equity ticker on Stocktwits. Retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume improved to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:936/103;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_10_090740_png_d70c080d0b.webp" alt="ENVB’s Sentiment Meter and Message Volume as of 09:00 a.m. ET on Dec. 10, 2025 | Source: Stocktwits" width="936" height="103"><figcaption>ENVB’s Sentiment Meter and Message Volume as of 09:00 a.m. ET on Dec. 10, 2025 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user said that if the drug proves safe and effective, a potential buyout exceeding $1 billion could be possible.&nbsp;<stembedurl>https://stocktwits.com/Luckyjs38/message/638708222</stembedurl>Another user expressed optimism about the low float and fresh IP update.&nbsp;<stembedurl>https://stocktwits.com/Caicong/message/638709397</stembedurl>ENVB stock has lost over 90% of its value year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-beat-stock-rocket-72-in-pre-market-today/cLIH2RhREV2">Why Did BEAT Stock Rocket 72% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Various substances are placed on cooling blocks in the PCR laboratory of the State Office for Agriculture, Food Safety and Fisheries.

Why Did ENVB Stock More Than Double In Value Today?

The company received a Notice of Allowance from the United States Patent and Trademark Office for its patent application.

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During J.P. Morgan Week 2026

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders...

Enveric Biosciences Announces Reverse Stock Split

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

ENVB
Enveric Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ENVB News

ENVBEnveric Biosciences Inc